The use of metaraminol bitartarate to blockade the hypotension produced by the levomepromazine HCL in dogs
DOI:
https://doi.org/10.11606/issn.1678-4456.bjvras.1994.52099Keywords:
Metaraminol, Levomepromazine, Anaesthesia, DogsAbstract
The aim of this work was evaluate the possibility of the use of the metaraminol bitartarate to blockade the decrease of the blood pressure produced by levomepromazine HCL in dogs. To this 20 crossbreed adult dogs, males and females, with average weight from 8 to 12 kg, were separated in two groups with 10 dogs each (GI and G1I). To the GI was administered, intravenously, 2 mg/kg of levomepromazine. Fifteen minutes after was administered, by the same way, 0.5 ml of saline solution (0.9%). The systolic blood pressure (PA), heart rate (FC), respiratory frequency (FR), body temperature (T) and eletrocardiographic analysis (Dll) was evaluated before and after the administration of the levomepromazine at 15 minutes of intervals, during 60 minutes. To the GII was applied the same method but the saline solution was replaced by the metaraminol at 0.1 mg/kg, administered by the intravenous way. The numeric data was evaluated by the profile analysis as statistic method. The results showed that the metaraminol increase the blood pressure and decrease the heart rate. The respiration and the body temperature were not changed with the use of metaraminol and the drugs administered did not produce eletrocardiographic alterations. The conclusion is that the use of metaraminol is indicated after the use of levomepromazine in dogs.Downloads
Download data is not yet available.
Downloads
Published
1995-06-02
How to Cite
Nunes, N., Pompermayer, L. G., Pirolo, J., & Rahal, S. C. (1995). The use of metaraminol bitartarate to blockade the hypotension produced by the levomepromazine HCL in dogs. Brazilian Journal of Veterinary Research and Animal Science, 32(2), 120-124. https://doi.org/10.11606/issn.1678-4456.bjvras.1994.52099
Issue
Section
ANIMAL PATHOLOGY
License
The journal content is authorized under the Creative Commons BY-NC-SA license (summary of the license: https://